Blog

New blood disorder warnings appear on Covid-19 vaccine made by Johnson & Johnson

New blood disorder warnings appear on the Johnson and Johnson (Janssen) Covid-19 vaccine label, now that the federal “pause” on administering the vaccine has ended.

The warnings flag an increased risk of thrombosis, clotting of the blood in the circulatory system. This disorder can be combined with thrombocytopenia, or low blood platelet count, which can lead to dangerous internal bleeding, according to the new warnings. The warnings say the symptoms can appear approximately one to two weeks after vaccination.

A 56-year old Miami Beach doctor, Gregory Michael, died of the rare blood disorder two weeks after his Dec. 18 vaccination with a different brand: Pfizer/BioNTech’s Covid-19 vaccine. However, his official cause of death was ruled to be “natural.” Dr. Michael was described as “very healthy” before his Covid-19 vaccine and sudden onset of “immune thrombocytopenia,” or low blood platelet count. There is no word as to whether officials have reclassified or reinvestigated his death.

One reason why relatively rare reports of a serious adverse event are cause for such concern and added warnings is that scientists have documented that they only capture a small percentage of actual illnesses that occur.

Each recognized case is presumed to represent many more that are not correctly diagnosed or reported to the Vaccine Adverse Event Reporting System or VAERS. Patients and doctors are encouraged to report all illnesses after vaccination to VAERS, whether they are proven to be linked to the inoculation or not. As professionals comb through the data, they are able to identify previously unknown side effects.

Several European countries report similar blood clot complications after use of AstraZeneca’s Covid-19 vaccine.

Keep reading

‘It’s the biggest thing in the history of the internet’: Pentagon quietly transfers 175 million internet addresses worth $4BILLION to mysterious firm at shared workspace in Florida

A very strange thing happened on the internet the day President Joe Biden was sworn in. 

A shadowy company residing at a shared workspace above a Florida bank announced to the world´s computer networks that it was now managing a colossal, previously idle chunk of the internet owned by the U.S. Department of Defense.

That real estate has since more than quadrupled to 175 million addresses – about 4 percent the size of the entire current internet. It’s also more than twice the size of the internet space actually used by the Pentagon.

‘It is massive. That is the biggest thing in the history of the internet,’ said Doug Madory, director of internet analysis at Kentik, a network operating company.

The sell off of Internet space sparked theories the Pentagon could be eventually responding to repeated demands to monitise its collections of millions of dormant web pages. 

But it now seems officials hope to place the pages on the open market in order to allow them to gather huge amounts of intelligence data about Internet users, including hostile actors.   

The military hopes to ‘assess, evaluate and prevent unauthorized use of DoD IP address space,’ said a statement issued Friday by Brett Goldstein, chief of the Pentagon’s Defense Digital Service, which is running the project. 

But it has not answered many basic questions, beginning with why it chose to entrust management of the address space to a company that seems not to have existed until September.

Keep reading

French drug assessment center demands removal of all four widely used COVID vaccines

A regional independent drug assessment center, the CTIAP (Centre territorial d’Information indépendante et d’Avis pharmaceutiques), which is linked to the Cholet public hospital in the west of France, recently published a report showing that the vaccines used against COVID were not only submitted to insufficient clinical testing, but that the quality of the active substances, their “excipients, some of which are new,” and the manufacturing processes are problematic. “These new excipients should be considered as new active substances,” the Cholet hospital team stated, in a study that according to them raises issues that have not been commented to date.

The team led by Dr. Catherine Frade, a pharmacist, worked on public data released by the EMA with relation to the Pfizer, Moderna, AstraZeneca and Janssen (Johnson & Johnson) shots, and its first caveat was that all these products only have temporary marketing authorizations. They are all subject to further studies that reach as far as 2024 and even beyond, and these will be almost impossible to be completed because of the way the vaccines are now being distributed, said the CTIAP report.

These studies even include the stability and comparability of the vaccine batches put on the market and the quality and safety of excipients — substances formulated alongside the active ingredient of a medication to facilitate or enhance their absorption.

According to the CTIAP, all of the vaccines were put on the market and actively used on human beings before “proof of quality for the active substance and the finished product” was produced: all the manufacturing labs obtained future deadlines to submit their studies in this regard.

Keep reading